drugset / Trial / NCT00785772

A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment

NCT00785772

Phase 4 Terminated 1 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objectives of this study are to evaluate the pharmacokinetics (PK) following administration of gabapentin in Japanese epileptic patients with renal impairment to confirm if there are any clinically relevant differences between the plasma gabapentin concentration simulated by population PK model, which was used for the evidence of the dose adjustment for the patients with renal impairment, and observed plasma gabapentin concentration.

Timeline

Start
2010-03
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Small molecule 100 mg
Subject Gabapentin Small molecule 200 mg
Subject Gabapentin Small molecule 400 mg
Subject Gabapentin Small molecule 500 mg
Subject Gabapentin Small molecule 1000 mg